ERBB2 and breast cancer: When focusing on the distribution of PAM50 intrinsic subtypes in HER2-low tumors, we noticed that the distribution of intrinsic subtypes within HER2-low/HR+ BC was more similar to the one of HER2−/HR+ BC, rather than to HER2-low/HR− BC, and this is reassuring for clinical practice, since, thus far, HER2-low/HR+ BC are ascribed to HER2−/HR+ BC for the purpose of treatment.